Bionano Genomics (BNGO) Expected to Release Earnings on Tuesday

Bionano Genomics (NASDAQ:BNGO) is expected to be releasing its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.45) per share and revenue of $8.44 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

Bionano Genomics (NASDAQ:BNGO) last released its earnings results on Monday, August 10th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.03. The company had revenue of ($6.67) million during the quarter, compared to analysts’ expectations of $7.55 million. Bionano Genomics had a negative return on equity of 78.78% and a negative net margin of 106.58%.

Bionano Genomics Trading Up 2.6%

Shares of BNGO stock traded up $0.03 on Tuesday, reaching $1.19. The company had a trading volume of 57,861 shares, compared to its average volume of 446,378. The company has a 50-day moving average of $1.37 and a 200-day moving average of $1.24. The stock has a market cap of $16.64 million, a PE ratio of -0.39 and a beta of 1.66. Bionano Genomics has a 12 month low of $1.00 and a 12 month high of $2.23. The company has a current ratio of 2.48, a quick ratio of 1.96 and a debt-to-equity ratio of 0.11.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BNGO. Weiss Ratings raised Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. Wall Street Zen raised Bionano Genomics to a “hold” rating in a research report on Saturday, September 26th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $6.00.

Bionano Genomics Company Profile

Bionano Genomics, Inc is a life sciences company that develops genomic analysis tools designed to help researchers and clinicians detect large-scale structural variations in DNA. Its technology is intended to complement or extend conventional sequencing and cytogenetic methods by providing information about changes in genome structure, including deletions, duplications, inversions and translocations.

The company’s principal platform is the Saphyr system, an optical genome mapping solution that analyzes ultra-high-molecular-weight DNA.